Bridging the Gap: Improving Clinical Development and the Regulatory Pathways for Health Products for Neglected Diseases
There has been tremendous progress over the last decade in the development of health products for neglected diseases. These include drugs, vaccines, and diagnostics for malaria and tuberculosis, which kill millions of people annually, plus other diseases like changes and dengue fever, which may less familiar, but nonetheless exact a large and often lethal toll in the worldâ€™s poorest communities. Led by product development public- private partnerships (PDPs) and fueled by the support of the Bill & Melinda Gates Foundation, the National Institutes of Health, and other donors, there are now dozens of candidate products in the pipeline. [Working Paper No. 217]
When requesting a correction, please mention this item's handle: RePEc:ess:wpaper:id:2640. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Padma Prakash)
If references are entirely missing, you can add them using this form.